Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ATM |
Variant | G1676fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | ATM G1676fs results in a change in the amino acid sequence of the Atm protein beginning at aa 1676 of 3056, likely resulting in premature truncation of the functional protein (UniProt.org). G1676fs has not been characterized, however, due to the effects of other truncation mutations downstream of G1676 (PMID: 16603769), is predicted to lead to a loss of Atm protein function. |
Associated Drug Resistance | |
Category Variants Paths |
ATM mutant ATM inact mut ATM G1676fs |
Transcript | NM_000051.4 |
gDNA | chr11:g.(108299733_108299734) |
cDNA | c.(5026_5025) |
Protein | p.G1676fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_011542840.4 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
XM_006718843.5 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
NM_000051.4 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
XM_005271562.6 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
XM_006718843.5 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
XM_017017790.3 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
NM_001351834.2 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
XM_047426976.1 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
XM_047426976.1 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
XM_011542843.3 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
XM_017017790.3 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
XM_011542840.4 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
NM_000051.4 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
NM_001351834.2 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
XM_005271562.6 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
XM_011542843.3 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
XM_047426975.1 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
XM_047426975.1 | chr11:g.(108299733_108299734) | c.(5026_5025) | p.G1676fs | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM G1676fs | cholangiocarcinoma | predicted - sensitive | Talazoparib | Case Reports/Case Series | Actionable | In a Phase II trial, Talzenna (talazoparib) treatment resulted in a clinical benefit rate (CBR) of 22.8% (18/79, 1 complete and 7 partial responses, 10 with stable disease >/=24 weeks) in patients with advanced solid tumors harboring mutations in DNA damage repair genes, including a partial response lasting 16 weeks in a cholangiocarcinoma cancer patient harboring ATM G1676fs (PMID: 39085400; NCT02286687). | 39085400 |